BioElectronics Corporation
BIEL
Other OTC0.00
USD
+0.00
- -
ISIN
US09062H1086
CUSIP
09062H108
Return %
Stock
S&P500
1Y
150.00
26.53
3Y
-20.00
76.60
5Y
-84.62
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Kelly A. Whelan
- Full Time Employees
- 9
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 4539 Metropolitan Court Frederick MD United States of America 21704
- IPO Date
- Apr 12, 2004
- Website
- bielcorp.com
- Similar Companies
- Business
- BioElectronics Corporation develops and commercializes electroceutical medical devices based on wearable, non-thermal pulsed shortwave therapy (PSWT) technology. Its core products include RecoveryRx, a class II FDA-cleared device for drug-free postoperative pain and edema management; ActiPatch, for musculoskeletal pain relief; Smart Insole, for foot care; Allay, designed for menstrual pain; and HealFast, a product line targeting veterinary applications for cats, dogs, and horses. The company's products provide non-invasive, extended duration therapy to reduce pain, inflammation, swelling, and accelerate tissue repair for human and veterinary markets. Headquartered in Frederick, Maryland, and founded in 1988, BioElectronics operates internationally with notable distribution agreements including those in Spain through PRIM Group and in Mexico via Novro Med for its RecoveryRx device. The company targets hospitals, clinics, the VA healthcare system, consumer healthcare, veterinary markets, and chronic pain sufferers across North America and Europe. Recent strategic developments include the expansion of sales channels for RecoveryRx into the U.S. Veterans Affairs system and veterinary markets, supported by promising clinical trial results demonstrating significant pain relief in humans and animals. The company has also established key international distribution partnerships driving adoption of RecoveryRx in Europe and the Middle East. Operationally, BioElectronics has terminated a contract with a previous partner due to performance issues and is pursuing potential legal action against Mundipharma for breach of contract. Clinical studies and research initiatives continue to underpin product innovation, regulatory compliance, and market expansion efforts. BioElectronics Corporation’s portfolio leverages FDA clearance, CE marking, Health Canada approval, and UK NHS reimbursement status, affirming its regulatory compliance across key markets. Its non-invasive electroceutical devices serve chronic neurological disorder patients and support postoperative recovery, chronic wound healing, and pain management, positioning the company within the medical device and bioelectronic therapy segments. This comprehensive approach to technology, clinical validation, and international partnerships positions BioElectronics as a growing player in electroceutical medical devices focused on drug-free pain management and rehabilitation solutions.
Simon Yeung of BIEL Crystal, Among 2025 Asia-Pacific U30 Outstanding Young Leaders Honoured At APEC
Sree Koneru, PhD Joins the Board of Directors of BioElectronics Corporation
BioElectronics Corporation's Chairman Updates Investors
BioElectronics Corporation Announces the Publication of a Canine Arthritis Study
BioElectronics Corporation Announces the Publication of Pilot Study Results
BioElectronics Chairman Updates Investors
End of Year Message From the Chairman of the Board of BioElectronics